Louise O'Reilly
Ceist:1055. Deputy Louise O'Reilly asked the Minister for Health if she plans to introduce screening for prostate cancer via the PSA test; and if she will make a statement on the matter. [6119/26]
Amharc ar fhreagraTuesday, 27 January 2026
Ceisteanna (1055)
Freagraí scríofa
I am committed to supporting our population screening programmes, which are a valuable part of our health service, enabling early treatment and care for many people, and improving the overall health of our population.
The Programme for Government commits to undertake a review of European screening and early detection programmes including for prostate and gastric cancers, to guide any further expansion of screening programmes. It also commits to research, implement and evaluate cancer prevention and early detection initiatives, including prostate cancer.
I would note that any proposed changes to Ireland’s screening programmes, including the potential introduction of a prostate cancer screening programme, will be facilitated through established evidence-driven protocols.
The National Screening Advisory Committee (NSAC) is the independent expert group that considers proposed changes to Ireland’s screening programmes. NSAC assesses the evidence in a robust and transparent manner and against internationally accepted criteria, before making recommendations to myself as Minister.
NSAC continues to progress work to consider the further expansion of our cancer screening programmes and has submitted several requests to the Health Information and Quality Authority (HIQA).
In December 2025, HIQA submitted the final report of its Health Technology Assessment (HTA) on the proposed extension of the BowelScreen age range eligibility to NSAC for its consideration. I look forward to receiving a recommendation from the Committee in this regard shortly.
HIQA have also commenced an evidence review to consider changes to the BreastCheck programme. This review will comprise of two elements; a proposed expansion of the age range eligibility to those aged 45-49 and 70-74, and the potential introduction of a standardised breast density notification. Both elements are anticipated to be complex and will take time to ensure that any recommendations made to me by NSAC are underpinned by a robust evidence-base.
HTAs facilitate the assessment of relevant evidence and knowledge on the effects and consequences of healthcare technologies to guide decisions regarding the appropriate use of technology and efficient allocation of resources. They involve a multi-disciplinary assessment of the clinical, economic, ethical, legal and societal perspectives that may be impacted by the introduction of a new technology. They are time intensive and rigorous processes.
In relation to prostate cancer screening, I welcome the involvement of Irish-based researchers in the EU4Health funded project, titled PRAISE-U, which is exploring the feasibility of risk-stratified screening for prostate cancer to help reduce morbidity and mortality caused by the disease, while avoiding overdiagnosis and unnecessary treatment.
Across Europe, several major research initiatives are underway to assess the feasibility of prostate cancer screening programmes, many involving Irish-based researchers. The findings from these studies will contribute to the evidence base for future consideration by NSAC. I look forward to receiving a recommendation from the Committee in due course.
Finally, I would emphasise that screening programmes are for people without symptoms. If anyone becomes aware of symptoms, or if they have concerns or worries, they should contact a medical professional immediately.